Biopharmaceutical company focused on developing treatments for rare genetic disorders of obesity.
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company in its commercial phase, specializes in developing and bringing to market treatments for rare genetic obesity disorders. The company's primary focus is IMCIVREE, its leading therapeutic candidate targeting the melanocortin-4 receptor. IMCIVREE is designed to address conditions such as pro-opiomelanocortin (POMC) deficiency obesity, proprotein convertase subtilisin/kexin type 1 deficiency obesity, leptin receptor (LEPR) deficiency obesity, as well as Bardet-Biedl syndrome and Alström syndrome.
Additionally, Rhythm Pharmaceuticals is advancing setmelanotide through Phase II clinical trials. Setmelanotide aims to treat a range of conditions including heterozygous POMC or LEPR deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other disorders associated with MC4R.
The company operates under a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome, highlighting its commitment to advancing scientific understanding and treatment options for these rare genetic disorders.
Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals was originally known as Rhythm Metabolic, Inc. before rebranding in October 2015. With a strong foundation in research and development, Rhythm Pharmaceuticals continues to lead efforts in addressing the unmet medical needs of patients affected by severe and rare forms of genetic obesity.